Literature DB >> 20418727

Elevated caspase-3 expression and T-cell activation in elite suppressors.

Rollie E Ronquillo, Seema N Desai, Philip J Norris, Elizabeth T Golub, Ruth M Greenblatt, Stephen J Gange, Alan L Landay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20418727      PMCID： PMC3228601          DOI： 10.1097/QAI.0b013e3181cbd469

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  11 in total

1.  Activation-induced CD4+ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4+ T cell count, and HIV plasma viral copy number.

Authors:  D H Dockrell; A D Badley; A Algeciras-Schimnich; M Simpson; R Schut; D H Lynch; C V Paya
Journal:  AIDS Res Hum Retroviruses       Date:  1999-11-20       Impact factor: 2.205

Review 2.  Suicidal tendencies: apoptotic cell death by caspase family proteinases.

Authors:  B B Wolf; D R Green
Journal:  J Biol Chem       Date:  1999-07-16       Impact factor: 5.157

3.  Preferential apoptosis of HIV-1-specific CD4+ T cells.

Authors:  Feng Yun Yue; Colin M Kovacs; Rowena C Dimayuga; Xiao Xiao Jenny Gu; Paul Parks; Rupert Kaul; Mario A Ostrowski
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

4.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

Review 5.  Emerging roles of caspase-3 in apoptosis.

Authors:  A G Porter; R U Jänicke
Journal:  Cell Death Differ       Date:  1999-02       Impact factor: 15.828

6.  Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation.

Authors:  Amanda J Chase; Hung-Chih Yang; Hao Zhang; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

7.  Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.

Authors:  Priscilla Y Hsue; Peter W Hunt; Amanda Schnell; S Craig Kalapus; Rebecca Hoh; Peter Ganz; Jeffrey N Martin; Steven G Deeks
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

8.  A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.

Authors:  Jason B Dinoso; Scott Y Kim; Robert F Siliciano; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

9.  Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

10.  Pro-caspase-3 is a major physiologic target of caspase-8.

Authors:  H R Stennicke; J M Jürgensmeier; H Shin; Q Deveraux; B B Wolf; X Yang; Q Zhou; H M Ellerby; L M Ellerby; D Bredesen; D R Green; J C Reed; C J Froelich; G S Salvesen
Journal:  J Biol Chem       Date:  1998-10-16       Impact factor: 5.157
View more
  2 in total

1.  Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study.

Authors:  Seema N Desai; Jennifer L Dodge; Alan L Landay; Marshall J Glesby; Patricia S Latham; Maria C Villacres; Audrey L French; Stephen J Gange; Ruth M Greenblatt; Marion G Peters
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

2.  Attenuation of pathogenic immune responses during infection with human and simian immunodeficiency virus (HIV/SIV) by the tetracycline derivative minocycline.

Authors:  Julia L Drewes; Gregory L Szeto; Elizabeth L Engle; Zhaohao Liao; Gene M Shearer; M Christine Zink; David R Graham
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.